查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1542916

全球預測診斷市場 - 2024-2031

Global Predictive Diagnostics Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預測診斷市場規模

全球預測診斷市場2023年達到486.7億美元，預計2031年將達到1,391.8億美元，2024-2031年預測期間複合年成長率為14.70%。

預測診斷採用客製化資料和一套診斷設備來提供精確、即時的見解並識別潛在問題。透過整合分子創新、基因組學應用和快速研發流程，預測診斷可以幫助為營運帶來有影響力和可衡量的進步。

使用預測診斷，所應用的演算法可以分析和識別所提供的資料中的模式，並計算未來即將發生故障的機率。預測診斷的主要應用是疾病管理。

預測診斷市場動態

不斷增加的產品發布和公司之間的合作

主要公司之間不斷增加的產品發布和合作預計將推動市場成長。公司正在採取合作、夥伴關係和收購等策略來擴大市場成長。

For instance, in September 2022, QIAGEN and Neuron23 Inc., a biotechnology organization focused on designing precision medicines for genetically defined neurological and immunological diseases, agreed to create a companion diagnostic for Neuron23's brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson's疾病.

此外，Tempus 還推出了新的 DPYD 演算法，作為其不斷成長的實驗室開發的預測演算法測試集合的最新成員。因此，預計上述因素將在預測期內推動市場成長。

缺乏預測診斷的專業知識

複雜的預測診斷結果可能難以解釋，特別是對於非該領域專業人士的從業人員。如果臨床醫生不完全理解這些結果，他們可能會發現很難將這些結果納入患者照護方案中。如果醫療保健專業人員缺乏足夠的培訓或預測診斷經驗，他們可能不願意為患者訂購這些測試。這可能會導致這些測試的使用率較低並阻礙市場的擴展。

預測診斷市場區隔分析

全球預測診斷市場根據類型、應用、最終用戶和地區進行細分。

腫瘤學領域預計將主導市場成長

腫瘤學領域佔據最大的市場佔有率。癌症是全世界最主要的死亡原因。最常見的癌症是乳癌、結腸癌、肺癌、直腸癌和攝護腺癌，2020 年死亡人數接近 1,000 萬人，佔六分之一。

這些公司正在推出各種用於腫瘤學的產品和平台，隨著癌症病例的不斷增加，對這些產品的需求增加，這可以擴大其應用範圍。

例如，2023 年 4 月，Certis Oncology Solutions 推出了 CertisAI，這是一個新的預測醫學平台，利用巨量資料、統計演算法和機器學習 (ML) 根據基因表現生物標記預測藥物療效。

此外，2021 年，Tempus 推出了新的 DPYD 演算法，作為其不斷成長的實驗室開發的預測演算法測試集合的最新補充。此測試評估 DPYD（二氫嘧啶脫氫酶）基因的相關突變，幫助醫生更好地識別某些化療藥物潛在毒性風險的患者，以避免不良反應。因此，對癌症診斷的日益關注預計將推動預測期內該細分市場的成長。

預測診斷市場地理分析

預計北美將在預測診斷市場佔有率中佔據重要地位

北美在預測診斷市場上佔據主導地位，預計在預測期內也將呈現相同的趨勢。改善的醫療基礎設施、不斷上升的傳染病發病率、活躍的區域主要參與者以及該地區方便的產品供應是推動該地區市場的主要因素。

例如，2021 年 6 月，Predictive Health Diagnostics Company, Inc. 與分銷合作夥伴 Patia Europe SL 合作推出了第二個診斷測試 DIABETESpredict。

此外，例如，2021年12月，羅氏收購了TIB Molbiol Group。 TIB Molbiol 將繼續作為診斷部門的子公司開展工作。羅氏和 TIB Molbiol 將打造快速開發新病原體和潛在健康威脅（例如傳染病）檢測方法的能力。因此，上述因素正在推動市場成長，並有望使該地區保持主導地位。

COVID-19 對預測診斷市場的影響分析

由於全球對 COVID-19 診斷的關注，診斷的必要性已得到更廣泛的認知。這使得人們充分認知到預測診斷在其他領域的可能性。 COVID-19 診斷的快速發展引發了分子診斷和人工智慧 (AI) 等領域的創新。這些進展可用於建立新的、增強的預測診斷儀器。 COVID-19 檢測能夠識別感染患者，這引起了人們對應用類似策略來早期診斷其他疾病（包括慢性病）的興趣。

預測診斷市場競爭格局

市場的主要全球參與者包括 Abbott Laboratories、Certis Oncology Solutions, Inc.、Proteomics International Laboratories Ltd、QIAGEN NV、Prometheus Laboratories Inc.、F. Hoffmann-La Roche Ltd.、Illumina Inc.、Myriad Genetics、Exact Sciences Corporation和信實生命科學公司。除其他外。

為什麼購買報告？

根據類型、應用程式、最終用戶和地區可視化全球預測診斷市場細分，並了解關鍵商業資產和參與者。

透過分析趨勢和共同開發來識別商業機會。

Excel資料表，包含所有細分市場預測診斷市場層級的大量資料點。

PDF 報告由詳盡的質性訪談和深入研究後的綜合分析組成。

產品映射以 Excel 形式提供，包含所有主要參與者的關鍵產品。

全球預測診斷市場報告將提供約 53 張表格、47 張圖和 176 頁。

2024 年目標受眾

製造商/買家

產業投資者/投資銀行家

研究專業人員

新興公司

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 不斷增加的產品發布和公司之間的合作
    • 限制
      • 缺乏預測診斷的專業知識
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 報銷分析
  • 專利分析
  • SWOT分析
  • DMI 意見

第 6 章：COVID-19 分析

第 7 章：按類型

  • 症狀前
  • 趨勢

第 8 章：按申請

  • 心血管疾病
  • 神經系統疾病
  • 遺傳疾病
  • 腫瘤學
  • 其他

第 9 章：最終用戶

  • 診斷中心
  • 基因實驗室和診所
  • 研究和學術機構

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • Abbott Laboratories
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Certis Oncology Solutions, Inc.
  • Proteomics International Laboratories Ltd
  • QIAGEN NV
  • Prometheus Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina Inc.
  • Myriad Genetics
  • Exact Sciences Corporation
  • Reliance Life Sciences. (LIST NOT EXHAUSTIVE)

第 13 章：附錄

簡介目錄
Product Code: CD1123

Predictive Diagnostics Market Size

The Global Predictive Diagnostics Market reached US$ 48.67 billion in 2023 and is expected to reach US$ 139.18 billion by 2031, growing at a CAGR of 14.70% during the forecast period 2024-2031.

Predictive diagnostics employs customized data and a suite of diagnostic devices to deliver precise, real-time insights and identify potential problems. By integrating molecular innovations, genomics applications, and rapid R&D processes, predictive diagnostics can assist in delivering impactful and measurable advancements to operations.

Using predictive diagnostics, the applied algorithms can analyze and recognize patterns within delivered data and calculate probabilities of upcoming failures in the future. The main application of predictive diagnostics is disease management.

Predictive Diagnostics Market Dynamics

The increasing product launches and collaborations among companies

Increasing product launches and collaborations among the major companies are expected to drive market growth. Companies are adopting strategies such as collaborations, partnerships, and acquisitions to expand the market growth.

For instance, in September 2022, QIAGEN and Neuron23 Inc., a biotechnology organization focused on designing precision medicines for genetically defined neurological and immunological diseases, agreed to create a companion diagnostic for Neuron23's brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson's disease.

Additionally, Tempus unveiled its new DPYD algorithm as its most recent addition to its growing collection of predictive algorithm laboratory-developed tests. Thus, the above factors are expected to drive the market growth during the forecast period.

Lack of expertise in predictive diagnostics

Complex predictive diagnostic results might be difficult to interpret, particularly for practitioners who are not professionals in this field. Clinicians can find it difficult to incorporate these outcomes into patient care regimens if they do not fully comprehend them. Healthcare professionals could be reluctant to order these tests for their patients if they lack enough training or experience with predictive diagnostics. This may result in a low use of these tests and impede the expansion of the market.

Predictive Diagnostics Market Segment Analysis

The global predictive diagnostics market is segmented based on type, application, end-user and region.

Oncology segment is expected to dominate the market growth

The oncology segment accounts for the largest market share. Cancer is the foremost cause of death worldwide. The most common cancers are breast, colon, lung, rectum, and prostate Cancer accounted for almost 10 million deaths in 2020 or nearly one in six.

The companies are introducing a variety of products and platforms to make use in oncology, as there is a growing number of cancer cases, the demand for these products rises which can expand their application.

For instance, in April 2023, Certis Oncology Solutions launched CertisAI, a new predictive medicine platform that utilizes big data, statistical algorithms, and machine learning (ML) to predict drug efficacy based on gene expression biomarkers.

Additionally, in 2021, Tempus introduced its new DPYD algorithm as its most recent addition to its growing collection of predictive algorithm laboratory-developed tests. The test assesses for relevant mutations in the DPYD (dihydropyrimidine dehydrogenase) gene and helps physicians better identify patients at potential risk for toxicity to certain chemotherapies, aiming to avoid adverse effects. Thus, increasing focus on cancer diagnostics is expected to drive the segment growth during the forecast period.

Predictive Diagnostics Market Geographical Analysis

North America is expected to hold a significant position in the predictive diagnostics market share

North America dominates the market for predictive diagnostics and is anticipated to show an equivalent trend over the forecast period. Improved healthcare infrastructure, rising infectious illness rates, active regional key players, and convenient product availability in the area are the main factors driving the market in the region.

For instance, in June 2021, Predictive Health Diagnostics Company, Inc. launched its second diagnostic test, DIABETESpredict, in collaboration with distribution partner Patia Europe SL.

Additionally, For instance, in December 2021, Roche acquired the TIB Molbiol Group. TIB Molbiol will continue to work as a subsidiary within the Diagnostics division. Roche and TIB Molbiol will create their capabilities for the fast development of assays for emerging pathogens and potential health threats, such as infectious diseases. Thus, the above factors are driving the market growth and are expected to hold the region in the dominant position.

COVID-19 Impact Analysis On Predictive Diagnostics Market

The necessity of diagnostics in general has become more widely recognised due to the global focus on COVID-19 diagnosis. This caused people to fully recognize the possibilities of predictive diagnoses in other fields. Innovations in fields like molecular diagnostics and artificial intelligence (AI) were sparked by the quick development of COVID-19 diagnostics. These developments can be used to create fresh, enhanced predictive diagnostic instruments. The ability of COVID-19 testing to identify infected patients has raised interest in applying comparable strategies for the early diagnosis of other diseases, including chronic ailments.

Predictive Diagnostics Market Competitive Landscape

The major global players in the market include Abbott Laboratories, Certis Oncology Solutions, Inc., Proteomics International Laboratories Ltd, QIAGEN N.V., Prometheus Laboratories Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., Myriad Genetics, Exact Sciences Corporation, and Reliance Life Sciences. among others.

Why Purchase the Report?

To visualize the global predictive diagnostics market segmentation based on type, application, end user and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of predictive diagnostics market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global predictive diagnostics market report would provide approximately 53 tables, 47 figures and 176 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing product launches and collaborations among companies
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of expertise in predictive diagnostics
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Presymptomatic *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Predispositional

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cardiovascular Diseases*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Neurological Diseases
  • 8.4. Genetic Diseases
  • 8.5. Oncology
  • 8.6. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Diagnostic Centers*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Genetic Laboratories and Clinics
  • 9.4. Research and Academic Institutes

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
      • 10.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
      • 10.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
      • 10.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.3.1. U.S.
      • 10.2.3.2. Canada
      • 10.2.3.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
      • 10.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
      • 10.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.4.1. Germany
      • 10.3.4.2. UK
      • 10.3.4.3. France
      • 10.3.4.4. Italy
      • 10.3.4.5. Spain
      • 10.3.4.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
      • 10.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
      • 10.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.4.1. Brazil
      • 10.4.4.2. Argentina
      • 10.4.4.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
      • 10.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
      • 10.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.4.1. China
      • 10.5.4.2. India
      • 10.5.4.3. Japan
      • 10.5.4.4. Australia
      • 10.5.4.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
      • 10.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
      • 10.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
      • 10.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Certis Oncology Solutions, Inc.
  • 12.3. Proteomics International Laboratories Ltd
  • 12.4. QIAGEN N.V.
  • 12.5. Prometheus Laboratories Inc.
  • 12.6. F. Hoffmann-La Roche Ltd.
  • 12.7. Illumina Inc.
  • 12.8. Myriad Genetics
  • 12.9. Exact Sciences Corporation
  • 12.10. Reliance Life Sciences. (LIST NOT EXHAUSTIVE)

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us